Search results
Added:
7 months ago
Navigate the rapidly evolving treatment landscape for hypertrophic cardiomyopathy with Dr Anjali Tiku Owens, a renowned expert in inherited cardiovascular diseases and advanced heart failure.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, explores both established and emerging therapeutic approaches for obstructive and non…
View more
ESC HFA 25: SCD-PROTECT
Added:
1 year ago
Video
Added:
1 year ago
ESC 2024 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, US) for a concise and insightful summary of the hot-line and late-breaking data that is expected to have an impact on heart failure care.Trials covered in detail include:FINEARTS HFHELIOS-BRESHAPE-HF2Recorded on-site at ESC Congress 2024, London.Editors: Jordan Rance and Mirjam Boros…
View more
Added:
1 year ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in…
View more
Added:
1 week ago
HFA Congress 2026 — Dr Lars Lund (Karolinska Institute and Karolinska University Hospital, Stockholm, SE) joins us to discuss findings from GOAL-HF1, a randomised, double-blind, placebo-controlled phase 1b/2a trial evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF).This first-in-patient study assessed the safety, tolerability and exploratory efficacy of AC01 — a…
View more
Added:
1 week ago
HFA Congress 2026 — Dr Nir Uriel (NewYork-Presbyterian, New York, US) discusses findings from a comparative analysis evaluating survival outcomes in middle-aged and older patients with advanced heart failure treated with left ventricular assist device (LVAD) therapy or heart transplantation.Drawing on two prospectively collected data sets: the Momentum 3 trial (HeartMate 3) and the UNOS…
View more
Added:
7 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in…
View more
Added:
5 days ago
Heart Failure Association Congress 2026 — Dr Philippe Debonnaire (AZ Sint Jan, Brugge, BE) and Professor Victoria Delgado (University Hospital Germans Trias i Pujol, Badalona, SP) discuss the expanding role of advanced cardiac imaging in heart failure diagnosis and management, and what a more personalised, multimodality approach means for clinical practice.The conversation moves beyond…
View more
Added:
5 months ago
Explore the diagnostic and therapeutic complexities of cardiac sarcoidosis with Prof Emer Joyce.This presentation, part of the comprehensive Cardiomyopathies track, tackles the persistent challenges in cardiac sarcoidosis, emphasizing that despite decades of clinical experience, diagnosis remains the field's greatest hurdle.Prof Joyce explores the heterogeneous clinical phenotypes capable of…
View more